Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

Abstract

These results suggest that tumors associated with BRCA1 mutations may be divided into two distinct groups, triple-negative and non-triple-negative groups. Future studies should seek to determine whether patients with BRCA1 mutations and triple-negative breast cancer respond to treatment better than BRCA-negative patients with similar tumor pathology.

Oncogenes and Tumor Suppressor Genes

“…These mice develop mammary tumors with full penetrancy and a median tumor latency of 6.3 months (Shafee et al 2008). In line with recent reports (Atchley et al 2008;Tung et al 2010), both ERa-positive and ERa-negative tumors were identified and p63 expression was up-regulated. These findings raise the possibility that the cells of origin in BRCA1-mediated breast carcinogenesis may be heterogeneous.…”

“…Earlier studies indicated that the majority of BRCA1-associated cancers are triple (ERa, PR, and HER-2) negative, basal-type breast cancers (reviewed in Lynch et al 2008). However, recent reports show that BRCA1-associated breast cancers can be ERa-and PR-positive, especially in aged patients (Atchley et al 2008;Tung et al 2010). The BRCA1 gene encodes a protein of 1863 amino acids with a predicted molecular weight of 220 kDa (Miki et al 1994).…”

Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study

“…tumours that do not express estrogen and progesterone receptor genes or the tyrosine kinase HER-2/neu) than BRCA2-related and sporadic breast cancers (87). Triplenegative tumours are more often poorly differentiated and associated with poorer survival (88).…”

RareBRCA1haplotypes including 3’UTR SNPs associated with breast cancer risk

“…6 Overall, breast tumors resulting from BRCA1 mutations are most frequently TN (57%), 7 or ER + breast cancers (34%), 8 and are rarely HER2 + breast cancers (about 3%). 9 While TN tumors are often characterized by low expression of BRCA1, 10 because BRCA1 mutations are quite rare, they only account for approximately 10-20% of the TN tumors.…”